Sarita U Patil1, Johanna Steinbrecher2, Agustin Calatroni3, Neal Smith2, Alex Ma2, Bert Ruiter4, Yamini Virkud5, Michael Schneider6, Wayne G Shreffler4. 1. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass; Food Allergy Science Initiative at Broad Institute at Massachusetts Institute of Technology and Harvard, Boston, Mass. Electronic address: sarita.patil@mgh.harvard.edu. 2. Food Allergy Center, Massachusetts General Hospital, Boston, Mass. 3. Rho, Chapel Hill, NC. 4. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Center for Immunology & Inflammatory Diseases, Massachusetts General Hospital, Boston, Mass; Food Allergy Science Initiative at Broad Institute at Massachusetts Institute of Technology and Harvard, Boston, Mass. 5. Food Allergy Center, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass; Food Allergy Science Initiative at Broad Institute at Massachusetts Institute of Technology and Harvard, Boston, Mass. 6. BÜHLMANN Laboratories, Schönenbuch, Switzerland.
Abstract
BACKGROUND: Only some patients with peanut allergy undergoing oral immunotherapy (OIT) achieve sustained clinical response. Basophil activation could provide a functional surrogate of efficacy. OBJECTIVE: We hypothesized that changes in basophil sensitivity and area under the curve (AUC) to the immunodominant allergen Ara h 2 correlate with clinical responses to OIT. METHODS: Children with peanut allergy aged 7 to 13 years were enrolled in a single-center, open-label peanut OIT trial. Levels of specific immunoglobulins were measured throughout OIT. Peripheral blood from multiple time points was stimulated in vitro with peanut allergens for flow cytometric assessment of the percentage of CD63hi activated basophils. RESULTS: Twenty-two of 30 subjects were successfully treated with OIT; after avoidance, 9 achieved sustained unresponsiveness (SU), and 13 had transient desensitization (TD). Basophil sensitivity, measured by using the dose that induces 50% of the maximal basophil response, to Ara h 2 stimulation decreased from baseline in subjects with SU (after OIT, P = .0041; after avoidance, P = .0011). At 3 months of OIT, basophil sensitivity in subjects with SU decreased from baseline compared with that in subjects with TD (median, 18-fold vs 3-fold; P = .01), with a receiver operating characteristic of 0.84 and optimal fold change of 4.9. Basophil AUC to Ara h 2 was suppressed after OIT equally in subjects with SU and those with TD (P = .4). After avoidance, basophil AUC rebounded in subjects with TD but not those with SU (P < .001). Passively sensitized basophils suppressed with postavoidance SU plasma had a lower AUC than TD plasma (6.4% vs 38.9%, P = .03). CONCLUSIONS: Early decreases in basophil sensitivity to Ara h 2 correlate with SU. Basophil AUC rebounds after avoidance in subjects with TD. Therefore, different aspects of basophil activation might be useful for monitoring of OIT efficacy.
BACKGROUND: Only some patients with peanutallergy undergoing oral immunotherapy (OIT) achieve sustained clinical response. Basophil activation could provide a functional surrogate of efficacy. OBJECTIVE: We hypothesized that changes in basophil sensitivity and area under the curve (AUC) to the immunodominant allergen Ara h 2 correlate with clinical responses to OIT. METHODS:Children with peanutallergy aged 7 to 13 years were enrolled in a single-center, open-label peanut OIT trial. Levels of specific immunoglobulins were measured throughout OIT. Peripheral blood from multiple time points was stimulated in vitro with peanut allergens for flow cytometric assessment of the percentage of CD63hi activated basophils. RESULTS: Twenty-two of 30 subjects were successfully treated with OIT; after avoidance, 9 achieved sustained unresponsiveness (SU), and 13 had transient desensitization (TD). Basophil sensitivity, measured by using the dose that induces 50% of the maximal basophil response, to Ara h 2 stimulation decreased from baseline in subjects with SU (after OIT, P = .0041; after avoidance, P = .0011). At 3 months of OIT, basophil sensitivity in subjects with SU decreased from baseline compared with that in subjects with TD (median, 18-fold vs 3-fold; P = .01), with a receiver operating characteristic of 0.84 and optimal fold change of 4.9. Basophil AUC to Ara h 2 was suppressed after OIT equally in subjects with SU and those with TD (P = .4). After avoidance, basophil AUC rebounded in subjects with TD but not those with SU (P < .001). Passively sensitized basophils suppressed with postavoidance SU plasma had a lower AUC than TD plasma (6.4% vs 38.9%, P = .03). CONCLUSIONS: Early decreases in basophil sensitivity to Ara h 2 correlate with SU. Basophil AUC rebounds after avoidance in subjects with TD. Therefore, different aspects of basophil activation might be useful for monitoring of OIT efficacy.
Authors: Thanh D Dang; Mimi Tang; Sharon Choo; Paul V Licciardi; Jennifer J Koplin; Pamela E Martin; Tina Tan; Lyle C Gurrin; Anne-Louise Ponsonby; Dean Tey; Marnie Robinson; Shyamali C Dharmage; Katrina J Allen Journal: J Allergy Clin Immunol Date: 2012-03-03 Impact factor: 10.793
Authors: B L Wright; M Kulis; K A Orgel; A W Burks; P Dawson; A K Henning; S M Jones; R A Wood; S H Sicherer; R W Lindblad; D Stablein; D Y M Leung; B P Vickery; H A Sampson Journal: Allergy Date: 2016-06-13 Impact factor: 13.146
Authors: Alexandra F Santos; Louisa K James; Henry T Bahnson; Mohammed H Shamji; Natália C Couto-Francisco; Sabita Islam; Sally Houghton; Andrew T Clark; Alick Stephens; Victor Turcanu; Stephen R Durham; Hannah J Gould; Gideon Lack Journal: J Allergy Clin Immunol Date: 2015-02-07 Impact factor: 10.793
Authors: Veronique Bajzik; Hannah A DeBerg; Nahir Garabatos; Blake J Rust; Kimberly K Obrien; Quynh-Anh Nguyen; Colin O'Rourke; Alex Smith; Alex H Walker; Charlie Quinn; Vivian H Gersuk; Mary Farrington; David Jeong; Brian P Vickery; Daniel C Adelman; Erik Wambre Journal: Allergy Date: 2022-03-14 Impact factor: 14.710